The investors and partners behind IHCV are drawn from the top echelons of the international financial and medical fields. They are all strong supporters of Israel-based scientific and medical development, in academia and in commercial enterprises. Their commitment to IHCV portfolio companies extends beyond financial backing as they are uniquely placed to help open doors to global medical and financial expertise and resources.
The members of the Investment Committee are Isaac Kaye, Warren Roiter, Steven Kaye, and Dr. Hadar Ron.
Mr. Isaac Kaye: Isaac Kaye, a pharmaceutical chemist, built one of the largest generic pharmaceutical companies in Europe which later merged with IVAX Corporation. Mr Kaye served IVAX as Deputy CEO and Deputy Chairman. IVAX merged with Teva in 2005 when it was valued in the sum of $7.4bn. Mr Kaye was one of the founder partners of IHCV. He has been a prominent supporter of Hebrew University of Jerusalem for more than 40 years and an active promoter of Israeli based technology and innovation. He established the Kaye innovation Awards in 1993 to encourage and recognise the achievements of Israeli scientists.
Mr. Steven Kaye: Mr. Kaye is a founding partner of Stockton Partners Inc. (New York) and a strategic advisor and member of the general partner of Trevi Health Ventures (new York), two venture capital firms that focus on medical technologies, pharmaceuticals and diagnostics. He is also a partner in Baystone Associates Ltd, a London-based asset management company. Mr. Kaye served in a variety of roles and ultimately as Director of Strategic Development at Norton Healthcare, the UK subsidiary of Ivax Corporation. Mr. Kaye graduated cum laude from Brandeis University and the London School of Economics with a BA degree in political science. He received his MBA degree from the University of Southern California.
Mr. Warren Roiter: Mr. Roiter founded and was for 30 years the Senior Partner of a London based law firm which specialised in advising pharmaceutical biotech and healthcare companies. He was actively involved in many of the leading patent and IP cases in the UK and Europe. Mr. Roiter has had a vast experience of a wide range of commercial matters and transactions involving the industry over a great many years. He was highly acclaimed in his field and was regarded as "the experts expert". He is a strategic adviser and member of the general partner of Trevi Health Ventures based in New York. Mr. Roiter retired from legal practice to concentrate on his business activities which includes his interests and involvement in IHCV and its investments.
Mr. Carlo Salvi (1936-2010): Mr. Salvi was a member of IHCV investment committee (2004-2010). Mr. Salvi was involved in the healthcare industry for over 40 years. Mr. Salvi founded Sicor and was its controlling shareholder prior to its acquisition by Teva in 2004. Following the acquisition, Mr. Salvi served on the Board of Directors of Teva and was one of its largest individual stockholders. Mr. Salvi was deeply involved in European and Israeli-based firms and had numerous CEO and board-level long-term relationships in the biotechnology and pharmaceutical fields.
IHCV benefited from his vast knowledge of the healthcare industry and significant venture capital investing experience and charming personality. We mourn his loss and cherish his memory.